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Abstract
Background & Aims
Occasional risk of serious liver dysfunction and autoimmune hepatitis during atorvastatin
therapy has been reported. We compared the risk of hepatotoxicity in atorvastatin relative to
simvastatin treatment.
Methods
The UK GPRD identified patients with a first prescription for simvastatin [164,407] or atorva-
statin [76,411] between 1997 and 2006, but with no prior record of liver disease, alcohol-
related diagnosis, or liver dysfunction. Incident liver dysfunction in the following six months
was identified by biochemical value and compared between statin groups by Cox regres-
sion model adjusting for age, sex, year treatment started, dose, alcohol consumption, smok-
ing, body mass index and comorbid conditions.
Results
Moderate to severe hepatotoxicity [bilirubin >60μmol/L, AST or ALT >200U/L or alkaline
phosphatase >1200U/L] developed in 71 patients on atorvastatin versus 101 on simva-
statin. Adjusted hazard ratio [AHR] for all atorvastatin relative to simvastatin was 1.9 [95%
confidence interval 1.4–2.6]. High dose was classified as 40–80mg daily and low dose 10–
20mg daily. Hepatotoxicity occurred in 0.44% of 4075 patients on high dose atorvastatin
[HDA], 0.07% of 72,336 on low dose atorvastatin [LDA], 0.09% of 44,675 on high dose sim-
vastatin [HDS] and 0.05% of 119,732 on low dose simvastatin [LDS]. AHRs compared to
LDS were 7.3 [4.2–12.7] for HDA, 1.4 [0.9–2.0] for LDA and 1.5 [1.0–2.2] for HDS.
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Data Availability Statement: Access to data from
General Practice Research Database (now called the
Clinical Practice Research Datalink/CPRD) is always
subject to a full licence agreement containing details
terms and conditions of use. The key principles
behind these are summarised below:- CPRD data
access licences are not transferable. Provision of
data is for use for public-benefiting medical research
only. An Independent Scientific Advisory Committee
(ISAC) protocol is required for all research which is in
any way to be communicated to others. A dataset
may only be used for the study for which it has been
approved. Attempts to identify patients, practices or
Conclusions
The risk of hepatotoxicity was increased in the first six months of atorvastatin compared to
simvastatin treatment, with the greatest difference between high dose atorvastatin and low
dose simvastatin. The numbers of events in the analyses were small.
Introduction
In the UK the National Institute for Health and Care Excellence [NICE] has recommended
that primary prophylaxis with atorvastatin should now be considered for all individuals
between the age of 30 to 84 years with a 10 year cardiovascular risk score of 10% or greater [1].
This has been estimated to include about 25% of this population and would constitute mass
medication of healthy individuals [2]. This guidance has stimulated controversy over possible
adverse effects of statins in a healthy population [3] and the observation that more information
is required. Statins are widely used and generally well tolerated. Adverse effects include myopa-
thy, an increased incidence of diabetes and an increase in serum transaminases [4].
Raised serum transaminases of hepatic origin are seen in about 1–3% of individuals treated
with statins but occasional more severe reactions can occur, with possible autoimmune hepati-
tis, resulting in hospitalisation and rare deaths [5–21]. Most studies looking at drug-induced
liver disease related to statins have relied on results from registration clinical studies or self-
reported adverse drug event registers [22–27] which may lead to under-reporting of events.
The UK General Practice Research Database [GPRD] offered an opportunity to retrospectively
examine all patients within a large sample population commenced on statin therapy in a “real
world setting” and allowed examination of the true incidence of severe biochemical abnormali-
ties associated with the use of atorvastatin. The GPRD became the Clinical Practice Research
Datalink [CPRD] in March 2012. Simvastatin was selected as the comparator to atorvastatin as
it is the most commonly prescribed statin in the UK and has few reports of hepatotoxicity.
Also the patient population prescribed the two drugs should be comparable eliminating many
other possible variables.
Patients and Methods
Study Design
A retrospective cohort study of the UK GPRD was undertaken comparing two groups of
patients commenced on atorvastatin or simvastatin between the 10-year period 1997 to 2006
with regard to the incidence of hepatic reactions within this group.
Study population
A total of 245,025 patients were identified on the GPRD who had a first prescription [index
date] for atorvastatin or simvastatin during the period 1st of January 1997 to the 31st of Decem-
ber 2006. Patients had to be permanently registered with the practice for at least twelve months
prior to the index date with no record of liver disease, alcohol-related diagnosis, statin prescrip-
tion or biochemical evidence of liver dysfunction prior to index date Table 1. Further exclusion
was made of patients under 18 years of age [n = 79] and patients with self-reported alcohol
consumption> 50 units/week [n = 1571]. To avoid counting prevalent hepatotoxicity, all
patients with a record of any of a list of selected liver-related conditions were censored 90 days
preceding the date of that condition code. As a result 118 patients were not included in the
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final analysis. A further 1234 patients were also not included for having a code recording an
alcohol-related diagnosis. This resulted in a final analysis population of 242,023 patients with
165,188 patients prescribed simvastatin and 76,835 patients prescribed atorvastatin. High dose
was classified as 40–80mg daily and low dose 10–20mg daily.
These patients were followed up until they either reached the end of the study period,
changed or stopped their prescribed statin, altered the dose of statin moving between low and
high dose groups, transferred out of their GP practice, died, or were within 90 days of having
a code recording liver disease that could not be drug induced [a post-exclusion event]. A
patient’s ‘on drug’ exposure period [defined by recorded prescriptions] ended either on the
day preceding the first change of statin or dose, or, if the statin was stopped altogether, 28
days after the date of the last statin prescription [because 28 days was the most common gap
between prescriptions]. This study reports data for the on-drug period only. Only 11% of
patients on simvastatin and 26% of patients on atorvastatin were censored due to a change to
the higher dose group during the six month period we analysed after initiation of therapy.
Several potential confounding factors such as age, sex, serum cholesterol, BMI, calendar
year of first prescription and comorbidity and baseline patient characteristics are shown in
Table 2.
The General Practice Research Database group has obtained blanket ethics approval for
observational studies using the General Practice Research Database and studies using the Gen-
eral Practice Research Database that result in publication require prior approval by the Inde-
pendent Scientific Advisory Committee, Medicines & Healthcare products Regulatory Agency,
151 Buckingham Palace Road, London, SW1W 9SZ, UK England.
The study was approved by General Practice Research Database research ethics committee:
Independent Scientific Advisory Committee Reference Number Protocol No. 08_039 [Appli-
cant Dr Peter Mills].
The data from General Practice Research Database is rigorously checked prior to release to
ensure it is anonymized with no patient identifiers. We did not approach patients directly for
consent as the data was supplied with licensed consent to use the data given by the Secretary of
State for Health.
Table 1. Exclusion criteria for patient selection prior to index date of statin prescription.
Alcohol related diagnosis
Pre-existing liver disease
 acute or chronic viral hepatitis
 autoimmune liver disease, primary biliary cirrhosis, autoimmune hepatitis, primary sclerosing
cholangitis
 extra-hepatic biliary obstruction
 metastatic liver disease
 haemochromatosis
 liver biopsy or transplant
Abnormal liver function:
 bilirubin levels >25 μmol/L
 AST levels >120 U/L
 ALT levels >120 U/L
 Alkaline Phosphatase levels >300 U/L
Previous prescription of any statin
doi:10.1371/journal.pone.0151587.t001
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Definition of outcomes
Hepatotoxicity was defined as first evidence of abnormal liver biochemistry with either a
serum bilirubin 40 μmol/l, serum aspartate aminotransferase [AST] or alanine aminotrans-
ferase [ALT] 120 U/l [3 x ULN] or serum alkaline phosphatase [ALP]> 2 x ULN or 600
U/l. Our cut-off values were primarily based upon local laboratory levels and we used 3 times
the upper limit of normal for AST/ALT, 2 x the upper limit of normal for ALP and a bilirubin
of over 40 [higher than our laboratory upper limit of normal] to try to counter possible small
differences in regional definitions of normal/abnormal enzyme levels.
Our primary endpoint was an episode of at least moderate hepatotoxicity which was a
serum bilirubin 60 μmol/l, serum AST or ALT 200 U/l [5 x ULN] or serum alkaline
phosphatase> 4 x ULN or 1200 U/l within the first six months of follow-up after initiation
of therapy. Other secondary endpoints defined as mild or severe liver dysfunction are catego-
rised in Table 3.
In patients with laboratory evidence of abnormal hepatic function as above, the results were
divided into three subcategories. Any one laboratory result at any point will qualify for inclu-
sion in that category.
Table 2. Baseline characteristics of patients on simvastatin and atorvastatin grouped by statin dose.
Data
Complete
Simvastatin Simvastatin Atorvastatin Atorvastatin
Dose 10–20 mg 40–80 mg 10–20 mg 40–80 mg
Total number 242023 100% 120367 44821 72741 4094
Age [years] Mean [SD] 100% 66 [12] 65 [12] 64 [12] 62 [13]
Sex Male 100% 61299
[50.9%]
24659 [55%] 37341
[51.3%]
2355
[57.55%]
BMI Mean [SD] 95% 27.9 [5.2] 28.3 [5.5] 28.3 [5.3] 28.2 [5.4]
Serum cholesterol [mmol/
L]
Mean [SD] 85% 6.3 [1.1] 6.2 [1.2] 6.5 [1.2] 6.5 [1.6]
Alcohol [U/wk] Mean [SD] 55% 8.8 [9.5] 9.3 [9.9] 8.9 [9.6] 10 [10.4]
Index year Mean [SD] 100% 2003.5 [2.6] 2005.1 [1.4] 2003.2 [2.1] 2004.9 [1.5]
Length of follow-up
[years]
Mean [SD] 100% 1.9 [2.0] 1.3 [1.2] 2.4 [1.9] 1.4 [1.3]
Medical history recorded Myocardial Infarct * 9969 [8.3%] 5146 [11.5%] 5516 [7.6%] 1088 [26.6%]
Coronary heart disease * 30158
[25.1%]
8962 [20%] 16953
[23.3%]
1076 [26.3%]
Cerebrovascular disease * 12183
[10.1%]
5459 [12.2%] 6973 [9.6%] 325 [7.9%]
Peripheral vascular disease * 3102 [2.6%] 1097 [2.4%] 1941 [2.7%] 100 [2.4%]
Diabetes mellitus * 25755
[21.4%]
9807 [21.9%] 18807
[25.8%]
636 [15.5%]
Hypertension * 62470
[51.9%]
22559
[50.3%]
36190
[49.7%]
1696 [41.4%]
MI within 30 days prior to index
date
* 3587 [3%] 3121 [7%] 1990 [2.7%] 808 [19.7%]
Any of MI, CHD, CVD, PVD * 44116
[36.6%]
16872
[37.6%]
25150
[34.6%]
2076 [50.7%]
SD—standard deviation.
*Medical history data completeness could not be calculated because non-occurrence could not be distinguished from non-recording of a condition
doi:10.1371/journal.pone.0151587.t002
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Data Analysis
The risk of reaching the primary endpoint was compared between patients being prescribed
atorvastatin and simvastatin by estimating hazard ratios with 95% confidence intervals [CI]
from Cox proportional hazards regression models. We investigated the possibility that a differ-
ence in risk between atorvastatin and simvastatin might depend upon statin dose by testing for
an interaction between prescribed statin and dose [high [40 to 80 mg] or low [10 to 20 mg]]
and estimating hazard ratios for high- and low-dose atorvastatin and high dose simvastatin rel-
ative to low dose simvastatin.
Atorvastatin has been reported to be more effective than simvastatin at lowering cholesterol
[28], and higher doses are more effective than lower doses [29], so patients with more severe
vascular disease, higher cholesterol levels or drug-resistant hypercholesterolaemia are more
likely to be prescribed atorvastatin and/or a high dose. We therefore expected to observe an
association between both prescribed statin, dose and risk of hepatotoxicity even in the absence
of a causal link [confounding by indication]. The statin-hepatotoxicity association is also
expected to be confounded by secular trends in statin prescribing patterns. We mitigated the
impact of confounders by adjusting hazard ratios for age in years [categorical: 18–50, 51–60,
61–70, 71–80, 81–90, 91], sex, year of first prescription [categorical: 1997–2001, 2002–2003,
2004–2006; boundaries were chosen to give approximately equal numbers of patients in each
category], self-reported alcohol consumption in units/week [categorical: 0, 1–7, 8–14, 15–21,
22], smoking habit [never, former, current], serum cholesterol level in mmol/L [categorical:<
5, 5–5.99, 6–6.99, 7], BMI in kg/m2 [categorical:< 25, 25–29.9, 30], histories of MI, coro-
nary heart disease, cerebrovascular disease, diabetes and hypertension and time of MI prior to
entry to the study [categorical: 0–30 days, 31 days-1 year, 1+ years, no history].
In addition to quantifying relative risks as hazard ratios, we estimated excess risk in terms of
absolute numbers of events by two methods. First, we estimated the number of events per 1000
patient-years of follow-up in each group as the predicted probability of a patient suffering an
event within six months [1 –S, where S is the probability of not experiencing an event within
six months] multiplied by 2000. Second, we estimated the number of patients that would need
to be treated [NNT] to predict an additional instance of hepatotoxicity. The NNT statistic was
calculated from the survival probabilities following equation 1 of Altman and Andersen [30]. It
is equivalent to the number needed to treat to cause harm to one patient compared with control
in a clinical trial, but differs in interpretation. For both analyses, survival probabilities were esti-
mated from a Cox regression model adjusted to a “typical” patient, that is, one who falls into
the most frequent category of each adjustment covariate [male, aged 61–70 years, never a
smoker, alcohol consumption not known, serum cholesterol 6–6.99 mmol/L, BMI 25–29.9 kg/
m2, no history of MI, CHD or CVD, a history of hypertension and index year 2004–2006]. 95%
confidence intervals for both statistics were estimated from 20,000 bootstrap replicates.
Because excluding patients with missing alcohol, serum cholesterol or BMI would have
reduced the size of the available data by 53%, we chose instead to fit missing alcohol, serum
cholesterol and BMI data as additional categories. We assessed the sensitivity of the results to
Table 3. Categorisation of abnormal liver biochemistry recorded after index date.
Hepatotoxicity Mild Moderate Severe
Bilirubin [μmol/L] 40–59 60–79 80
AST or ALT [U/L] 120–199 200–399 400
Alkaline Phosphatase 2–4 x ULN 4–6 x ULN >6 x ULN
[U/L] 600–1199 1200–1799 1800
doi:10.1371/journal.pone.0151587.t003
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this approach by re-estimating hazard ratios from the reduced data set. Smoking data could
not be dealt with in this way because too few data were missing [N = 1205] to allow estimation
of a hazard ratio, so patients with missing smoking data were excluded.
In an observational study it is never possible to adjust for all of the differences between
patients that affect outcome. We therefore expected the adjusted hazard ratios to be biased by
residual confounding. For example, patients are at increased risk of hepatotoxicity immediately
following a myocardial infarction, and such patients are more likely to be prescribed atorva-
statin and a high dose Table 2. We investigated this potential source of residual confounding
by re-estimating the adjusted hazard ratios after the exclusion of patients with a myocardial
infarction in the 30 days prior to first statin prescription. Another potential source of residual
confounding is the fact that where no clinical history is recorded we do not know whether this
is because the patient has no history or because the history has not been recorded in GPRD.
We assessed the sensitivity of the adjusted hazard ratios to missing clinical history by excluding
patients with no history of any of myocardial infarction, coronary heart disease, cerebrovascu-
lar disease or peripheral vascular disease. Where the numbers in the excluded subgroup were
sufficient, we tested for a significant difference in the hazard ratios between the included and
excluded subgroups.
Stratification of outcomes was performed according to statin dose to examine whether there
was a dose-related effect in determining adverse outcome. All statistical analyses were per-
formed using R version 2.13.0 [31].
Results
Moderate to severe hepatotoxicity for simvastatin and atorvastatin
71 [0.09%] of all 76411 patients on atorvastatin developed moderate or severe hepatotoxicity
versus 101 [0.06%] of all 164407 patients on simvastatin in the first six months on treatment
Table 4. The adjusted hazard ratio for atorvastatin relative to simvastatin was 1.9 [95% confi-
dence interval 1.4–2.6; p<0.001].
Moderate to severe hepatotoxicity in high versus low dose statin groups
Hepatotoxicity was more common in patients on 40–80 mg than 10–20 mg of either statin
[adjusted hazard ratio: 2.1; 95% CI 1.5–3.0; p<0.001] Table 5. The strength of the association
with prescribed statin was stronger at high doses [interaction p<0.001], with hepatotoxicity
Table 4. Hazard ratio [HR] estimates [95%CI] for significant lab events associated with atorvastatin during the first 6 months therapy on treatment,
relative to simvastatin.
Outcome N Prescribed statin P
Simvastatin Atorvastatin
164407 76411
Hepatotoxicity 240818 N [%] 407 [0.25%] 245 [0.32%]
All grades Unadj. HR 1 [ref] 1.2 [1.0, 1.4] 0.02
Adj. HR 1 [ref] 1.4 [1.2, 1.7] <0.001
Hepatotoxicity 240818 N [%] 101 [0.06%] 71 [0.09%]
Moderate to severe Unadj. HR 1 [ref] 1.4 [1.0, 1.9] 0.03
Adj. HR 1 [ref] 1.9 [1.4, 2.6] <0.001
1205 [0.5%] patients with missing smoking data were excluded.
N = number
doi:10.1371/journal.pone.0151587.t004
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being most common in patients on high dose atorvastatin. Moderate to severe hepatotoxicity
occurred in 18 [0.44%] of 4075 high dose atorvastatin patients in comparison to 53 [0.07%] of
72336 patient on low dose atorvastatin, in 39 [0.09%] of 44675 patients on high dose simvastatin
and 62 [0.05%] of 119732 patients on low dose simvastatin. Adjusted hazard ratios calculated rel-
ative to low dose simvastatin were 7.3 [4.2–12.7; p<0.001] for high dose atorvastatin, 1.4 [0.9–
2.0; p = 0.095] for low dose atorvastatin and 1.5 [1.0–2.2; p = 0.068] for high dose simvastatin.
The distribution of liver function test severity levels among the 172 patients who experi-
enced the primary endpoint of at least moderate hepatotoxicity with at least one of the four
tests within 6 months of initiation of statin therapy is given in S1 Table.
Numbers needed to harm
The number of instances of moderate to severe hepatotoxicity per 1000 patient-years of follow-
up was 0.9 [0.4–1.6] for low-dose simvastatin, 1.3 [0.6–2.3] for high-dose simvastatin, 1.2 [0.6–
2.1] for low-dose atorvastatin and 6.5 [2.8–11.9] for high-dose atorvastatin. The excess risk of
moderate to severe hepatotoxicity in the high dose atorvastatin group relative to low dose sim-
vastatin translates to one additional event in six months per 359 [95% CI 188–912] patients
treated. Cumulative incidence for moderate to severe hepatotoxicity for both atorvastatin and
simvastatin and also for high versus low dose groups over the first six months after index dose
is illustrated in Figs 1 and 2.
Effect/absence of significant vascular events on hepatotoxicity
The hazard ratios were not substantially affected by excluding patients suffering myocardial
infarction in the 30 days prior to statin treatment [S2 Table], although we could not formally
test this due to the low numbers of patients reaching an endpoint in the excluded subgroup
[14/9438 patients with recent MI suffered hepatotoxicity]. Similarly, excluding patients with
no history of vascular disease had no significant effect on the hazard ratios [interaction
p = 0.355; S3 Table].
Discussion
Hepatotoxicity was defined by laboratory test to include either a serum bilirubin>60 μmol/L, AST
or ALT>200 U/L or alkaline phosphatase>1200 U/L. This increased risk was predominantly
Table 5. Hazard ratio [HR] estimates [95%CI] for significant lab events associated with prescribed statin and dose during the first 6 months ther-
apy on treatment, relative to low dose simvastatin.
Outcome N Prescribed statin and dose
Simvastatin Simvastatin Atorvastatin Atorvastatin P
10–20 mg 40–80 mg 10–20 mg 40–80 mg
119732 44675 72336 4075
Hepatotoxicity 240818 N [%] 258 [0.22%] 149 [0.33%] 205 [0.28%] 40 [0.98%]
Unadj. HR 1 [ref] 1.6 [1.3, 2.0], P<0.001 1.2 [1.0, 1.5], P = 0.02 4.6 [3.3, 6.4], P<0.001 <0.001
All grades Adj. HR 1 [ref] 1.3 [1.0, 1.5], P = 0.03 1.3 [1.0, 1.5], P = 0.015 3.3 [2.3, 4.7], P<0.001 <0.001
Hepatotoxicity 240818 N [%] 62 [0.05%] 39 [0.09%] 53 [0.07%] 18 [0.44%]
Moderate to severe Unadj. HR 1 [ref] 1.7 [1.2, 2.6], P = 0.007 1.3 [0.9, 1.9], P = 0.13 8.6 [5.1, 14.6], P<0.001 <0.001
Adj. HR 1 [ref] 1.5 [1.0, 2.2], P = 0.07 1.4 [0.9, 2.0], P = 0.095 7.3 [4.2, 12.7], P<0.001 <0.001
1205 [0.5%] patients with missing smoking data were excluded.
N = number
doi:10.1371/journal.pone.0151587.t005
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Fig 1. Cumulative incidence of moderate-severe hepatotoxicity for atorvastatin and simvastatin [all
doses] over 6 months after index dose.
doi:10.1371/journal.pone.0151587.g001
Fig 2. Cumulative incidence of moderate-severe hepatotoxicity for atorvastatin and simvastatin [high
and low dose groups] over 6 months after index dose.
doi:10.1371/journal.pone.0151587.g002
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experienced by patients on high dose atorvastatin, although the numbers of events in the analyses
were small. 71 events [0.09%] were recorded on atorvastatin in comparison to 101 events [0.06%]
on simvastatin with an adjusted hazard ratio of 1.9 for atorvastatin in comparison to simvastatin.
There have been 40 cases in the published literature of significant hepatotoxicity due to stat-
ins [12] with one of the larger case series, suggesting concern over atorvastatin, published by
our group [5]. However, there is ongoing debate in the literature as to whether such concern
over hepatotoxicity due to statins has any foundation with the major cardiovascular trials often
quoted as demonstrating no safety concerns. It has been noted that the large trials devised for
evaluating morbidity and mortality benefits of statins in treating cardiovascular disease were
not designed with the intent of assessing the risk of drug-induced liver injury [DILI]. Similar
rates of abnormal liver function tests were observed between placebo and treatment arms of
large statin trials including EXCEL, the 4S study, the MIRACL study and WOSCOPS [32–35].
Since the large clinical statin trials, there have been studies looking specifically at the safety
of statins with respect to drug-induced liver injury. Hepatic injury due to statins was reported
by a group who analysed episodic reports of adverse drug reactions sent to the Swedish Adverse
Drugs Reactions Advisory Committee between 1988 and 2010 [24]. Their definition of hepato-
toxicity included transaminases five times the upper limit of normal or alkaline phosphatase at
twice the upper limit of normal. They found 73 patients with hepatotoxicity of whom 30 [41%]
were taking atorvastatin and 28 [38%] simvastatin with two deaths and one requirement for
liver transplant. They demonstrated overall statin-related hepatotoxicity in 1.6/100,000
patient-years, with 2.9 events/100,000 patient-years for atorvastatin and 0.9 events/100,000
patient-years for simvastatin. Our systematic study demonstrated a more frequent rate of mod-
erate to severe hepatotoxicity with 0.9 events/1000 patient-years for low-dose simvastatin [i.e.
90 events per 100000 patient-years compared to the rate of 0.9 events per 100000 patient years
seen for simvastatin in the Swedish study], 1.3 events/1000 patient-years for high-dose simva-
statin, 1.2 events/1000 patient-years for low-dose atorvastatin and 6.5 events/1000 patient-
years for high-dose atorvastatin. The excess risk of moderate to severe hepatotoxicity for a
patient on high dose atorvastatin group compared to a patient on low dose simvastatin trans-
lated to one additional hepatotoxic event in six months for every 359 patients treated. Our
study had a significantly higher rate of events than seen in the Swedish study and may reflect
our different methods and definitions. The Swedish study, as do most adverse event registries,
relied on the healthcare reporting of adverse events [and could feasibly under-report the fre-
quency of statin-related events] and cannot be compared directly with elevated liver function
tests in routine testing recorded on the GPRD. They also calculated the incidence of statin-
induced hepatotoxicity based on the total statin prescription data in Sweden during the study
period whereas we report the prescription data only for the subjects in a well defined GPRD
cohort. One final point of note is that the Swedish paper did include causality assessment by
means of the RUCAM score which led to exclusion of some patients due to incomplete clinical
data whereas we did not perform such an assessment.
Previous studies of drug-related adverse events have suggested that statins contribute to
between approximately 1 to 3% of all drug-induced liver injury. A study by Bjornsson et al [25]
reported on 784 cases of drug-induced liver injury and suspected statins in 8 [4 atorvastatin, 4
simvastatin] of these cases with two of the eight patients going to liver transplant and death
respectively. Andrade et al [26] prospectively examined 461 cases of drug-induced liver injury
reported to the Spanish Hepatotoxicity Registry, implicating statins in 18 cases [3%] and a sim-
ilar proportion of drug-induced liver injury [3.4%] was reported by Chalasani et al [27].
Previous studies have shown severe adverse hepatic events related to statins to be infre-
quent. The Acute Liver Failure Study Group reported on 133 prospectively collected cases of
acute liver failure due to drug-induced liver injury between 1998 and 2010 [36]. 2 patients
Atorvastatin Hepatotoxicity in Comparison to Simvastatin in UK GPRD
PLOSONE | DOI:10.1371/journal.pone.0151587 March 16, 2016 9 / 13
[1.5%] had taken atorvastatin, 2 had taken simvastatin and 2 had taken the now discontinued
cerivastatin. Interestingly, high ANA titres were seen in cases due to cerivastatin and simva-
statin, suggesting a possible drug-induced autoimmune phenomenon. Other groups have also
highlighted an apparent link between statins and autoimmune hepatitis [37–42].
A comparative safety analysis of 49 trials involving 14236 patients looked at the effect of
dosage on adverse events due to atorvastatin [43]. The incidence of any ALT or AST elevations
greater than 3 times the upper limit of normal was 0.6% in the atorvastatin 10 mg group, 0.6%
in the placebo group and 3.3% in the atorvastatin 80 mg group. The positive association
observed in this study between atorvastatin dose and hepatotoxicity incidence mirrors our own
findings.
A recent update by the Statin Liver Safety Task Force concluded that recorded hepatotoxic-
ity due to all statins was still a rare event The group reported that the FDA had conducted sev-
eral post-marketing reviews of statins and hepatotoxicity from 2000 to 2009 using the Agency’s
Adverse Event Reporting System [AERS] database. The reporting of statin-associated serious
liver injury to the AERS database was extremely low [reporting rate of less than two per one
million patient-years] [44]. This discrepancy with our own study may reflect the potential
under-reporting of adverse events in registries discussed previously in our paper.
One of the weaknesses of our study was the high frequency of missing data due to variation
among clinicians in recording data (Table 2). However, we assessed the impact of missing data
using sensitivity analyses. Another weakness of retrospective GPRD studies is that there is inev-
itably variation in reference ranges for laboratory values between different practices. To address
this we devised a set of laboratory criteria to reflect severe levels of liver injury. The degree of
liver dysfunction to qualify as moderate hepatotoxicity was quite stringent to ensure that the
large numbers with mild elevation of serum transaminases commonly seen with statins were
not observed as an end-point. Another final point of note is that our events per patient-years
calculation was based upon events recorded within six months of drug initiation. We analysed
the initial six months as previous case series have demonstrated that the majority of idiosyn-
cratic liver reactions are seen in the initial period after commencement of statin [12]. Given
that our mean length of follow-up was up to 2.4 years for low dose atorvastatin, 1.9 years for
low dose simvastatin, 1.4 years for high dose atorvastatin and 1.3 years for high dose simva-
statin, any events per patient-year calculation based upon all observed follow-up may have
been influenced by this variation in therapy duration between the different statin-dose groups.
In conclusion, patients on atorvastatin were found to have an overall increased risk of hepa-
totoxicity in comparison to those on simvastatin. This increased risk was predominantly expe-
rienced by patients on high dose atorvastatin with an incidence of biochemical hepatotoxicity
of 6.5 per 1,000 patient-years. This risk of measured hepatic events was significantly higher
than previously reported studies which were based upon healthcare reporting and may reflect
under-reporting in such systems. Low dose statin therapy appears to be relatively safer than
high dose atorvastatin in our study. However the absolute difference in risk is small.
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